Dispelling the Myths About Omega-3 Fatty Acids

References

• Arterbum L, Hall E, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006; 83(6 Suppl): 1467S–1476S.
   Web of Science ®Google Scholar
• Sampath H, Ntambi J. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev. 2004; 62(9): 333–339.
   PubMed Web of Science ®Google Scholar
• Bezard J, Blond J, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. Semin Nephrol. 1994; 34(6): 539–568.
   Google Scholar
• Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002; 277(11): 8755–8758.
   PubMed Web of Science ®Google Scholar
• Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008: 197(1): 12–24.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton P, Taylor D, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000; 71(1 Suppl): 179S–188S.
   PubMed Web of Science ®Google Scholar
• Harris WS. Fish oil supplementation: evidence for health benefits. Cleve Clin J Med. 2004; 71(3): 208–221.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006: 296(15): 1885–1889.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton P, Harris W, Appel L, American Heart Association (AHA), AHA Nutrition Committee. Fish consumption, fish oil, omega- 3 fatty acids, and cardiovascular disease. Circulation. 2002: 106(21): 2747–2757.
   PubMed Web of Science ®Google Scholar
• Mahaffey K. Fish and shellfish as dietary sources of methylmercury and the (0–3 fatty acids, eicosahexaenoic acid and docosahexaenoic acid: risks and benefits. Environ Res. 2004; 95(3): 414–428.
   PubMed Web of Science ®Google Scholar
• Monterey Bay Aquarium. Monterey Bay Aquarium seafood watch. Fish fact cards, www.seafoodwatch.org. Accessed July 2, 2007.
   Google Scholar
• Environmental Defense Fund. Oceans Alive: Salmon. http://www.oceansalive.org/eat.cfm?subnav=fishpage&group=salmon. Accessed July 2, 2007.
   Google Scholar
• Fish Oil Supplements. Med Lett Drugs Ther. 2006; 48(1239): 59–60.
   PubMed Web of Science ®Google Scholar
• Lovaza [package insert]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc. 2007.
   Google Scholar
• Vannice G. Omega-3 fatty acids from fish oil. Today's Dietitian. 2005; 7: 32.
   Google Scholar
• Food and Drug Administration. Compliance Program and Guidance Manual: Active Pharmaceutical ingredient (API) Process Inspection. Revision Summary. FDA Form 2438g(electronic-09/2003). http://www.fda.gov/cder/dmpq/7356-002f-CDER.pdf. Accessed March I, 2007.
   Google Scholar
• Reliant Pharmaceuticals, Inc. Data on file. Liberty Corner, NJ 07938.
   Google Scholar
• Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu Rev Nutr. 1988; 8: 517–541.
   PubMed Web of Science ®Google Scholar
• Neuringer M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA. 1986; 83(11): 4021–4025.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006; 63(11): 1545–1550.
   PubMedGoogle Scholar
• Simopoulos A. Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases. J Am Coll Nutrition. 2002; 21(6): 495–5005.
   PubMed Web of Science ®Google Scholar
• Bourre JM. Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress, depression, dementia and aging. J Nutr Health Aging. 2005; 9(1): 31–38.
   PubMed Web of Science ®Google Scholar
• Lin PY, Su KP. A meta-analytic review of double-blind, placebo- controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007; 68(7): 1056–1061.
   PubMed Web of Science ®Google Scholar
• SanGiovanni J, Chew E. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Research. 2005; 24(1): 87–138.
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008; 6(3): 391–409.
   PubMedGoogle Scholar
• Harris W. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989; 30(6): 785–807.
   PubMed Web of Science ®Google Scholar
• Miller M. Why triglycerides need to be aggressively managed: a guide for physicians. Cardiovasc Rev Rep. 2003; 24(10): 520–526.
   Google Scholar
• Jacobson TA. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? Mayo Clin Proc. 2006; 81(9): 1225–1231.
   PubMed Web of Science ®Google Scholar
• Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002; 112(4): 298–304.
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354(9177): 447–455.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567): 1090–1098.
   PubMed Web of Science ®Google Scholar
• Balk E, Chung M, Lichtenstein A. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence Report/Technology Assessment No. 93. Rockville, MD: AHRQ; 2004 (AHRQ publication no. 04-E10-2).
   Google Scholar
• Harris W, Ginsberg H, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4(5–6): 385–391.
   PubMedGoogle Scholar
• Von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2007; 10(2): 129–135.
   PubMed Web of Science ®Google Scholar
• Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115(11): 1481–1501.
   PubMedGoogle Scholar
• US Food and Drug Administration. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease (Docket No. 91N-0103). http://www.cfsan.fda.gov/-dms/ds-ltrl1.html. Published October 31, 2000. Accessed February 12, 2007.
   Google Scholar
• Harris W, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006; 17(4): 387–393.
   PubMed Web of Science ®Google Scholar
• Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003; 44(3): 455–463.
   PubMed Web of Science ®Google Scholar
• Jung UJ, Torrejon C, Tighe AP, Deckelbaum RJ. n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am J Clin Nutr. 2008; 87(6): 2003S–2009S.
   Web of Science ®Google Scholar
• Woo JJ. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview. Thromb Res. 2005; 117(1–2): 193–196; discussion 201–197.
   PubMed Web of Science ®Google Scholar
• Radimer KL, Subar AF, Thompson FE. Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III. J Am Diet Assoc. 2000; 100(4): 447–454.
   PubMedGoogle Scholar
• Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc. 2006; 106: 1966–1974.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Talk Paper: FDA finalizes rules for claims on dietary supplements, http://vm.cfsan.fda.gov/~lrd/tpdsclm.html. Accessed March 2, 2006.
   Google Scholar
• US Food and Drug Administration. Dietary Supplement Health and Education Act of 1994, Public Law 103–417, 103rd Congress: Available at http://www.fda.gov/opacom/laws/dshea.html. Accessed March 3, 2006.
   Google Scholar
• Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin. 2007; 23(5): 1139–1145.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA News: FDA announces qualified health claims for omega-3 fatty acids. September 8, 2004: 1–2.
   Google Scholar
• Burr M, Fehily A, Gilbert J, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989; 2(8666): 757–762.
   PubMed Web of Science ®Google Scholar
• Burr M, Sweetnam P, Fehiley A. Letter to the editor. Eur Heart J. 1994; 15: 1152–1154.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143–3421.
   PubMed Web of Science ®Google Scholar
• Harris W. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997; 65(5 Suppl): 1645S–1654S.
   PubMed Web of Science ®Google Scholar
• Borthwick L. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Invest. 1998; 15(5): 397–404.
   PubMed Web of Science ®Google Scholar
• Chan D, Watts G, Mori T, Barrett P, Beilin L, Redgrave T. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002; 32(6): 429–436.
   PubMed Web of Science ®Google Scholar
• Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr. 2000; 71 (4): 914–920.
   PubMed Web of Science ®Google Scholar
• Pownall H, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by co-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999; 143(2): 285–297.
   PubMed Web of Science ®Google Scholar
• Mackness M, Bhatnagar D, Durrington P, et al. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr. 1994; 48(12): 859–865.
   PubMed Web of Science ®Google Scholar
• Childs M, King I, Knopp R. Divergent lipoprotein responses to fish oils with various ratios of eicosapentaenoic acid and docosahexaenoic acid. Am J Clin Nutr. 1990; 52(4): 632–639.
   PubMed Web of Science ®Google Scholar
• Grimsgaard S, Bonaa K, Hansen J, Nordoy A. Highly purified eicosapentaenoic acid and docosahexanoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997; 66(3): 649–659.
   PubMed Web of Science ®Google Scholar
• Davidson M, Stein E, Bays H, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007; 29(7): 1354–1367.
   PubMed Web of Science ®Google Scholar
• Grundt H, Nilsen DW, Hetland O, et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J intern Med. 1995; 237(3): 249–259.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2): 213–219.
   PubMedGoogle Scholar
• Austin M, McKnight B, Edwards K, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation. 2000; 101(24): 2777–2782.
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005; 45(7): 1003–1012.
   PubMed Web of Science ®Google Scholar
• Jeppesen J, Hein H, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease—An eight-year follow-up in the Copenhagen Male Study. Circulation. 1998; 97(11): 1029–1036.
   PubMed Web of Science ®Google Scholar
• Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J. 2000; 140(2): 232–240.
   PubMed Web of Science ®Google Scholar
• Imazio M, Forno D, Quaglia C, Trinchero R. Omega-3 polyunsaturated fatty acids role in postmyocardial infarction therapy. Panminerva Med. 2003; 45: 99–107.
   PubMed Web of Science ®Google Scholar
• Arntz HR. Recommendations for secondary prevention after myocardial infarction. Z Kardiol. 2004; 93(suppl 1): I23–I25.
   PubMedGoogle Scholar
• Nordoy A, Bonaa K, Nilsen H, Berge R, Hansen J, Ingebretsen O. Effects of simvastatin and omega-3 fatty acids in plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 1998; 243(2): 163–170.
   PubMed Web of Science ®Google Scholar
• Durrington P, Bhatnagar D, Mackness M, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001; 85(5): 544–548.
   PubMed Web of Science ®Google Scholar
• Chan D, Watts G, Beilin L, Redgrave T, Mori T. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002; 51(8): 2377–2386.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Filipowicz BL, Edwards TJ, Hawkey CJ. High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers. Br J Clin Pharmacol. 1990; 30(2): 187–194.
   PubMed Web of Science ®Google Scholar
• Harris WS, Connor WE. The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance. Trans Assoc Am Physicians. 1980; 93: 148–155.
   PubMedGoogle Scholar
• Harris W, Windsor S. n-3 fatty acid supplements reduce chylomicron levels in healthy volunteers. J Atheroscler Thromb. 1991; 43(1): 5–15.
   Google Scholar
• Harris W, Connor W, Alam N, Illingworth D. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988; 29(11): 1451–1460.
   PubMed Web of Science ®Google Scholar
• Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the ω-6 and ω-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988; 82(6): 1884–1893.
   PubMed Web of Science ®Google Scholar
• Williams CM, Moore F, Morgan L, Wright J. Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects. Br J Nutr. 1992; 68(3): 655–666.
   PubMed Web of Science ®Google Scholar
• Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007; 99: S35C–S43C.
   Web of Science ®Google Scholar
• Consumer Lab.com. Product review: omega-3 fatty acids (EPA and DHA) from fish/marine oils, http://www.consumerlab.com/results/omega3.asp. Accessed April 23, 2007.
   Google Scholar
• US Food and Drug Administration. FDA issues dietary supplements final rule. FDA News. Available at http://www.fda.gov/bbs/topics/NEWS/2007/NEWO1657.html. Accessed June 29, 2007.
   Google Scholar
• Bryhn M, Hansteen H, Schanche T, Aakre S. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot Essent Fatty Acids. 2006; 75(1): 19–24.
   PubMed Web of Science ®Google Scholar
• Sanders T, Sullivan D, Reeve J, Thompson G. Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis. 1985; 5(5): 459–465.
   PubMedGoogle Scholar
• Zucker M, Bilyeu D, Helmkamp G, Harris W, Dujovne C. The effects of dietary fish oil on platelet function and plasma lipids in hyperlipo-proteinemic and normal subjects. Atherosclerosis. 1988; 73(1): 13–22.
   PubMed Web of Science ®Google Scholar
• Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long- term adherence with cardiovascular drug regimens. Am Heart J. 2006; 151(1): 185–191.
   PubMed Web of Science ®Google Scholar
• Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007; 99(6A): S44–46.
   PubMed Web of Science ®Google Scholar
• Vanschoonbeek K, Feijge M, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vase Biol. 2004; 24(9): 1734–1740.
   PubMed Web of Science ®Google Scholar
• Bender N, Kraynak M, Chiquette E, Linn W, Clark G, Bussey H. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998; 5(3): 257–261.
   PubMed Web of Science ®Google Scholar
• Vanschoonbeek K, Feijge MA, Saris WH, de Maat MP, Heemskerk JW. Plasma triacylglycerol and coagulation factor concentrations predict the anticoagulant effect of dietary fish oil in overweight subjects. J Nutr. 2007; 137(1): 7–13.
   PubMed Web of Science ®Google Scholar
• Mueller BA, Talbert RL. Biological mechanisms and cardiovascular effects of omega-3 fatty acids. Clin Pharm. 1988; 7(11): 795–807.
   PubMedGoogle Scholar
• Goodnight SH Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood. 1981; 58(5): 880–885.
   PubMed Web of Science ®Google Scholar
• Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis. 1984; 50(1): 3–10.
   PubMed Web of Science ®Google Scholar
• Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr. 1980; 33(12): 2657–2661.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Swearingen D, Spirito MD, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters (P-OM3). J Clin Pharmacol. 2006; 46(7): 785–791.
   PubMed Web of Science ®Google Scholar
• Williams C, Burdge G. Long-chain n-3 PUFA: plant v. marine sources. Proc Nutr Soc. 2006; 65(1): 42–50.
   PubMed Web of Science ®Google Scholar
• Smith S, Allen J, Blair S, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 (19): 2363–2372.
   Google Scholar